Novartis - Reimagining patient care and future directions in axSpA and PsA


Industry room 2
English
Satellite Symposia
03 June 2021 08:15 - 09:45

Learning Objective(s):  
 
Importance of understanding axial disease (axSpA and PsA with axial manifestation) in clinical practice  
 
Safety profile of IL-17A inhibition in the context of overall safety across approved indications 
 
Unmet needs and management approaches in patients with ERA and JPsA 
 
Evolving concepts in SpA, with a focus on innovation in patient care 

Presentations

Title Time Calendar .ics
Welcome and objectives of the session
03 June 2021 08:15 - 08:25 .ics
Understanding axial disease in clinical practice: does it matter?
03 June 2021 08:25 - 08:45 .ics
Putting patients first: safety of IL-17A inhibition
03 June 2021 08:45 - 09:05 .ics
Juvenile psoriatic arthritis and enthesitis-related arthritis: evolving concepts
03 June 2021 09:05 - 09:20 .ics
Reimagining patient care: committed to innovation
03 June 2021 09:20 - 09:40 .ics
Closing remarks
03 June 2021 09:40 - 09:45 .ics